Clinical Cardiology Alert – July 1, 2021
July 1, 2021
View Issues
-
Time of the Essence with Dapagliflozin for Heart Failure
By adding dapagliflozin to maximally tolerated standard therapy for heart failure with reduced left ventricular ejection fraction, researchers noted the reduction in mortality and recurrent heart failure began within one month of starting this therapy. -
Age Drives Stroke Risk in Atrial Fibrillation
Among patients with newly diagnosed atrial fibrillation age 66-74 years without other CHA2DS2-VASc risk factors for thromboembolism, the older they are in this age range, the more likely they are to experience a stroke. -
Aspirin, Clopidogrel, or Both After Coronary Interventions?
A recent study of patients who had undergone a percutaneous coronary intervention and were transitioning from dual antiplatelet therapy to monotherapy showed clopidogrel was superior to aspirin for preventing further major adverse events, including bleeding. -
FFR Fails to Show Benefit in Treatment of Nonculprit Lesions After STEMI
In this study of patients presenting with ST-elevation myocardial infarction and multivessel disease, nonculprit vessel percutaneous coronary intervention (PCI) guided by fractional flow reserve failed to show benefit vs. angiography-guided PCI in terms of clinical events at one year. -
Predicting Coronary Artery Disease in Breast Cancer Patients
The authors applied an automated algorithm to calculate an Agatston coronary artery calcium score from non-ECG-gated planning CT scans in breast cancer patients undergoing radiation therapy. This provided a graded risk calculation that could encourage preventive measures in patients at highest risk of a cardiovascular disease event.